| Theme | The State of the Art in Chemotherapy for Gastrointestinal Cancer | |
|---|---|---|
| Title | Adjuvant Chemotherapy for Colorectal Cancer ; Appropriate Treatment Regimens for Individual Patients | |
| Publish Date | 2011/06 | |
| Author | Hiroyuki Uetake | Departments of Translational Oncology, Graduate School, Tokyo Medical and Dental University |
| Author | Toshiaki Ishikawa | Departments of Translational Oncology, Graduate School, Tokyo Medical and Dental University |
| Author | Kenichi Sugihara | Department of Surgical Oncology, Graduate School, Tokyo Medical and Dental University |
| [ Summary ] | UFT／LV, capecitabine and S-1 are employed for adjuvant colorectal cancer chemotherapy in Japan. Oxaliplatin (l-OHP) regimens, have proven to be effective as elements of adjuvant chemotherapy for stage II and III colorectal cancer in Western countries and are now also available in Japan. There is still controversy as to whether all stage II and III patients should receive l-OHP regimens in this country. Biomarker studies may be helpful in selecting adequate regimens for individual patients receiving adjuvant therapy for colorectal cancer in the future. | |